HomeTrading IdeasDynamic Hedging and FX...

Dynamic Hedging and FX Risk Analysis Within Tactical Asset Allocation Rules

Often, investors fully hedge their portfolios for currency risk. This can lead to significant drag in performance for currencies with negative carry. However, not hedging the foreign currency exposure can lead to significant drawdowns, especially for conservative investments. In this paper, we consider a conservative, global tactical asset allocation strategy implemented in US dollar-denominated securities for a hypothetical European investor and highlight the benefits of dynamic currency hedging over static hedging. Using a parsimonious model for hedge ratio based on multiple features of merit and an explicit check for maximum allowed under-hedging, we show that a cost-aware, dynamic hedging strategy can reduce the hedging costs substantially while keeping the portfolio risk within mandate specifications.

In Optimal hedging with higher moments, the authors have looked at a general class of utility functions, HARA, and tried to optimize hedging rules to maximize that set of utility functions. The main contribution of that paper is to point out that if the strategy that is being hedged has significant positive skew or if the securities we are hedging with have a skewed distribution of returns, then we should look at higher moments in computing the hedge ratio.

As opposed to traditional OLS hedge ratios, a hedge ratio computed by HARA utility functions would exhibit lower risks and better hedging in out-of-sample data. The methods we have outlined here can be extended to higher moments as well. While others have highlighted that for a global multi-asset portfolio, making currency-hedging decisions asset by asset rather than for the overall portfolio could be sub-optimal, the actual optimal hedging calculation is done under long-term capital market assumptions, considering strategic portfolios.

Dynamic maximum allowed under-hedging – In this case, we propose a time-varying maximum allowed under-hedging, and that it should be a function of the expected volatility of the respective currency ( in this case).
We found that around 24% constant under-hedging achieves similar risk as the assumed risk guidance. All the features other than the difference in equity returns did better than the static hedging strategy in terms of performance, both in terms of returns and drawdown. These normalized features were generated with absolutely no look-ahead.

We found that if not using any optimization, the optimal results are obtained with all the weight given to the best feature 10 year yield difference. Since the equal-weighted feature combination has similar performance and is much more robust against any potential overfitting, we did not try to add regularization. Another important observation is that the performance of the dynamic hedging strategy based on short-term interest rate spread with and without look-ahead is quite similar, reinforcing the value of short-term interest rate spread in successfully predicting future cost of hedging.

Most Popular

More from Author

Gold Prices Rise on Trump’s Tariff Threats and Fed Policy Uncertainty

Tariff-Related Inflation Risks Support Gold Gold () rose by over 0.35% on...

US Dollar Holds Steady as Trump Threatens 50% Tariffs on Brazil

Trump announces fresh round of tariffs on Brazil and smaller nations But...

Read Now

Gold Prices Rise on Trump’s Tariff Threats and Fed Policy Uncertainty

Tariff-Related Inflation Risks Support Gold Gold () rose by over 0.35% on Wednesday. Markets remain focused on tariff demand letters from US President Donald Trump, with Brazil the latest country to face steep duties on and other imports. The tariffs have fuelled concerns about broader trade disruptions and...

FDA Grants Complete Approval To Moderna’s COVID-19 Vaccine For Children As Young As 6 Months – Moderna (NASDAQ:MRNA)

The U.S. Food and Drug Administration (FDA) has approved Moderna Inc.’s MRNA supplemental Biologics License Application (sBLA) for Spikevax, the company’s COVID-19 vaccine, in children six months through 11 years of age who are at increased risk for COVID-19 disease.The company’s COVID-19 vaccine, mRNA-1273, was previously available...

US Dollar Holds Steady as Trump Threatens 50% Tariffs on Brazil

Trump announces fresh round of tariffs on Brazil and smaller nations But only mild risk aversion as Nvidia (NASDAQ:) drives equities higher, hits $4 trillion cap Fed minutes erase July cut bets as doves in the minority, dollar supported Bitcoin hits record high, comes just shy of $112,000 Trump Stuck in...

The Market Everyone Gave Up On Is Crushing Nasdaq 100 In 2025 – Global X MSCI Greece ETF (ARCA:GREK), Invesco QQQ Trust, Series 1...

Greece's 2010 collapse was so severe it leased islands, gutted public jobs and pensions, while some abroad even joked about selling the Acropolis to appease creditors.Fast forward 15 years, and the picture couldn't be more different.The Athens Stock Exchange has soared nearly 34% year-to-date, making Greece the...

Pfizer, Astellas Report Xtandi Survival Win In Prostate Cancer Study – Pfizer (NYSE:PFE)

Pfizer Inc. PFE and Astellas Pharma Inc. ALPMF ALPMY on Thursday released topline results from the overall survival (OS) analysis from the Phase 3 EMBARK study evaluating Xtandi (enzalutamide), in combination with leuprolide and as a monotherapy, in men with non-metastatic hormone-sensitive prostate cancer with biochemical recurrence...

The Powell-Trump Clash is Set to Escalate

Growth challenges are mounting while tariffs will lift inflation, but stagflation fears are wide of the mark. The Fed will likely delay rate cuts until the end of the year, despite escalating pressure from the president, but may move in larger steps when it does cutConsumer Caution...

Why Is AbbVie Stock Trading Higher On Thursday? – AstraZeneca (NASDAQ:AZN), AbbVie (NYSE:ABBV)

IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation Inc., and AbbVie Inc. ABBV, on Thursday, announced an exclusive licensing agreement for IGI’s lead investigational asset, ISB 2001, developed using IGI’s proprietary BEAT protein platform, for oncology and autoimmune diseases.“Multispecifics including trispecific antibodies represent...

German CPI Confirmed at 2.0%, Euro Drifting, FOMC Split Over Cuts

The euro continues to have a quiet week and is drifting for a third consecutive day. In the European session, is trading at 1.1730, up 0.09% on the day.German Inflation Dips to 2% as food, Energy Prices FallGerman inflation rose 2.0% y/y in June, in line...

Klotho Stock Delivers 1,222% Biotech Blowout: Opportunity or Bubble? – Klotho Neurosciences (NASDAQ:KLTO)

Shares of Klotho Neurosciences, Inc. KLTO have soared more than 1000% over the past three months on promising results and breakthrough hopes. Klotho stock was in the spotlight again Thursday after announcing an FDA nod on its ALS treatment candidate. What's Driving The Rally: Klotho announced it has received...

Eurozone Economic Weakness Laid Bare as US Front-Loading Effects Wane

Eurozone data remains volatile amid trade war developments, but the underlying trend is still sluggish. Uncertainty is slowing domestic demand, which contributes to our expectation of a further rate cut from the European Central Bank in SeptemberEurozone Economy Shows Further Weakness in the Second QuarterThe eurozone economy...

SeaStar Medical’s QUELIMMUNE Wins Prestigious Award From The National Kidney Foundation, Former Winners Include Names Like Janssen, Merck and Otsuka – Johnson & Johnson...

When it comes to unmet needs in the nephrology space, acute kidney injury remains a significant concern. That's particularly true regarding pediatric AKI – each year, about 4,000 children with AKI require continuous renal replacement therapy (RRT), with a mortality rate of approximately 51-58%. Many of those...

Why Are Biotech Stocks Ultragenyx And Mereo Facing A Sell-Off? – Ultragenyx Pharmaceutical (NASDAQ:RARE), Mereo BioPharma Group (NASDAQ:MREO)

Ultragenyx Pharmaceutical Inc. RARE and Mereo BioPharma Group plc MREO stocks are plunging on Thursday.What Happened?The companies on Wednesday announced that the randomized, placebo-controlled Phase 3 portion of the Orbit study evaluating UX143 (setrusumab) in pediatric and young adult patients with osteogenesis imperfecta (OI) is progressing toward...